Current Research Studies
Click here for more information about our studies
HIV CURE
A5321: Decay of HIV-1 Reservoirs in Patients on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study. Closed to enrollment.
A5374: A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen with Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy during Acute HIV-1.
A5388: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined with ART Initiation during Acute HIV Infection to Induce HIV Remission.
A5389: A Phase I Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living with HIV Who Initiated ART During Acute/Early HIV-1 Infection
HIV Comorbidities and Complications
A5402: An Open-Label, Randomized Controlled Trial of Pramipexole versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD with Mild Neurocognitive Disorder (MND) in Persons with HIV: COPE
A5424: Menopausal Hormone Therapy for Women Living with HIV (HoT)
A5426: Improving Physical Ability and Cellular Senescence Elimination in HIV (IPACE-HIV)
HIV Treatment
A5359 (ARTS TSG): A Phase III Study to Evaluate Long-Acting Antiretroviral Therapy in Non-adherent HIV-Infected Individuals. Closed to enrollment
A5385: An Observational Post-Intervention Control Destination Cohort
Hepatitis B
A5394.(Hepatitis TSG): Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with Both Chronic Hepatitis B and HIV.
Non-ACTG Research Studies
GSK1265744: Phase 3b, open label, randomized, standard-of-care control arm, multicenter, superiority study evaluating the efficacy, safety and tolerability of injectable CAB LA + RPV LA in viremic participants living with HIV-1 (CROWN).
HPTN 103- GS-US-528-6363: A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics and Safety of Twice Yearly Long-Acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs